Stevanato Q3 Revenue Up 8% to €326.1M; FY26 Guidance Held, 2027 GLP-1 Growth Curbed
STVN is trading near its 52-week low of $12.89 (9.4% above the low) on elevated volume (11× avg).
Summary
Stevanato delivered 8% organic Q3 revenue growth to €326.1 million with adjusted EBITDA margin up 150 basis points to 27.2%, held its full-year 2026 guidance, but flagged lower-than-expected GLP-1 volumes that will temper growth in 2027.
Key Events · Earnings and Guidance · STVN
-
Q3 Revenue Grows 8% Organically
Revenue rose 8% to €326.1 million, entirely organic, with high-value solutions at 46% of total revenue.
-
Margins Expand, EPS Up 15%
Adjusted EBITDA margin rose 150 basis points to 27.2% on €88.8 million of adjusted EBITDA; diluted EPS grew 15% to €0.15 and adjusted diluted EPS 14% to €0.16.
-
Segment Split: BDS Up, Engineering Down
Biopharmaceutical and Diagnostic Solutions revenue grew 11% organically to €294.0 million, offsetting a 12% decline in Engineering revenue to €32.0 million.
-
FY26 Guidance Maintained
Full-year 2026 guidance unchanged: revenue €1.260-1.280 billion, adjusted EBITDA €335.0-345.2 million, adjusted diluted EPS €0.60-0.62.
Analysis · STVN · Industrial Applications And Services
Third-quarter results met management's expectations: organic revenue grew 8% to €326.1 million, adjusted EBITDA margin rose 150 basis points to 27.2%, and adjusted diluted EPS came in at €0.16 versus €0.14 a year ago. The forward view matters more. The CEO now expects lower GLP-1 volumes and revenue than previously assumed, which will temporarily moderate 2027 growth, though management says it has already backfilled much of the gap and still sees low-single-digit growth next year. Full-year 2026 guidance is unchanged at €1.260-1.280 billion of revenue and €0.60-0.62 of adjusted diluted EPS. The mix is uneven: Biopharmaceutical and Diagnostic Solutions grew 11% organically while the Engineering segment fell 12%, and GLP-1 therapies were roughly 17-18% of total revenue in the quarter.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, STVN was trading at $14.10 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $12.89 to $27.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.